The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MDS 2020 | EPO plus G-CSF treatment for MDS
Nicolas Bonadies
• 5 Mar 2020
Nicolas Bonadies, MD, Bern University Hospital, Bern, Switzerland, discusses the efficacy of combining granulocyte-colony stimulating factor (G-CSF) with erythropoietin (EPO) for low-risk myelodysplastic syndrome (MDS) patients. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.
